Is Trans Genic Inc. (2342.T) a Buy, Sell, or Hold?
Trans Genic Inc.
JPX:2342.T
$227 JPY
$2 (0.89%)
- Volume
- 49.1K
- Average Volume
- 231.28K
- Market Capitalization
- $3.78B
- P/E Ratio
- -49.01
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $487.00
- Year Low
- $168.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.74
Industry, Sector & symbol
| Stock Exchange | JPX |
| CEO | Kenji Fukunaga |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | 2342.T |
| CUSIP | None |
| CIK | None |
| Web | https://transgenic-group.co.jp |
| Phone | 81 9 2288 8470 |
| Currency | JPY |
| Employees | 227 |
| Country | JP |
Liquidity
| Debt-to-Equity Ratio | 0.44 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.74 |
| Quick Ratio | 1.10 |
| Cash Ratio | 0.55 |
Sales & Book Value
| Annual Sales | $13.17B |
| Price / Sales | 0.29 |
| Cash Flow | 0.00 |
| Price / Cash Flow | 0.00 |
| Price / Book | 0.79 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.64 |
| Trailing P/E Ratio | -49.01 |
| PEG Ratio | -0.31 |
| P/E Growth | -0.31 |
| Net Income | $-77.27M |
| Net Margin | -0.59% |
| Pretax Margin | -1.57% |
| Return on Equity | -1.60% |
| Return on Assets | -0.79% |
Financials Score
| AltmanZ Score | 2.33 |
| Piotroski Score | 5.00 |
| Working Capital | 2.86B |
| Total Assets | 9.74B |
| Ebit | 137.96M |
| Market Cap | 3.75B |
| Total Liabilities | 4.9B |
Poll Results
About Trans Genic Inc. (JPX:2342.T) Stock
Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and Investment Business. Within its Drug Discovery Support segment, the company offers a comprehensive array of services. These include the synthesis and analytical assessment of glycans (or sugar chains), alongside extensive non-clinical investigations crucial for pharmaceuticals, food products, cosmetics, and various chemical compounds. The firm conducts diverse safety evaluations for both food and pharmaceutical agents, and provides vital support for bioequivalence studies, encompassing clinical trials, pharmacokinetic measurements, and the compilati ... on of clinical trial reports. Hospital support services are also part of its offerings. Furthermore, Trans Genic performs drug efficacy and pharmacological testing, provides strategic advisory services covering mergers & acquisitions, business restructuring, and succession planning, and undertakes contract manufacturing of items such as genetically engineered mice, antibodies, protein hypers, and expression cells. It also markets mouse models, associated products, and research reagents. Established in 1998, the company was initially known as Kumamoto Immunochemical Laboratories Inc. before rebranding as Trans Genic Inc. in April 2000. Its corporate headquarters are located in Fukuoka City, Japan.
Frequently Asked Questions
-
What is the current Trans Genic Inc. (2342.T) stock price?
-
Trans Genic Inc.(JPX:2342.T) stock price is $227 in the last trading session. During the trading session, 2342.T stock reached the peak price of $487 while $168 was the lowest point it dropped to. The percentage change in 2342.T stock occurred in the recent session was 0.89% while the dollar amount for the price change in 2342.T stock was $2.
-
2342.T's industry and sector of operation?
-
The JPX listed 2342.T is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 2342.T?
-
Kazuo Watanabe | GM of Accounting & Finance Department and Director
Kenji Fukunaga | Chief Executive Officer, President & Representative Director
Shunichi Kitajima | Head of CRO Business Division, GM of Facility Management Office & Director
Yutaka Funabashi | GM of IR, Corporate Management Office & Information Management Office and Director
| -
How many employees does 2342.T have?
-
Number of 2342.T employees currently stands at 227. 2342.T operates from 2-3-36 Tenjin, Fukuoka City, FK 810-0001, JP.
-
Link for 2342.T official website?
-
Official Website of 2342.T is: https://transgenic-group.co.jp
-
How do I contact 2342.T?
-
2342.T could be contacted at phone #81 9 2288 8470 and can also be accessed through its website. 2342.T operates from 2-3-36 Tenjin, Fukuoka City, FK 810-0001, JP.
-
How many shares of 2342.T are traded daily?
-
The average number of 2342.T shares traded daily for last 3 months was 231.28K.
-
What is the market cap of 2342.T currently?
-
The market value of 2342.T currently stands at $3.78B with its latest stock price at $227